After Omeros decided to hit pause…
After Omeros decided to hit pause on developing its MASP-3 [...]
BioCryst Pharmaceuticals has…
BioCryst Pharmaceuticals has struck a $700 million deal to buy [...]
Kailera Therapeutics has raised…
Kailera Therapeutics has raised $600 million to take its lead [...]
Denali Therapeutics has become the…
Denali Therapeutics has become the latest on a growing list [...]
The California biotech is…
The California biotech is developing a new drug class in [...]
Tvardi Therapeutics has failed its…
Tvardi Therapeutics has failed its first big test as a [...]
Gilead and Arcus’ anti-TIGIT…
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to [...]
Novo Nordisk is ending all work in…
Novo Nordisk is ending all work in cell therapy, including [...]
Johnson & Johnson may be…
Johnson & Johnson may be looking to deepen its relationship [...]
Cabaletta Bio’s CAR-T cell…
Cabaletta Bio’s CAR-T cell therapy successfully eliminated the overreactive B [...]